{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:27:08Z","timestamp":1767706028902,"version":"3.40.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide\/emtricitabine\/rilpivirine (TAF\/FTC\/RPV), TAF\/FTC\/elvitegravir\/cobi (TAF\/FTC\/EVG\/cobi) and ABC\/lamivudine\/dolutegravir (ABC\/3TC\/DTG)] in a cohort of people living with HIV\/AIDS (PLWH) under effective ART.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All PLWH aged above 18\u2009years on antiretroviral treatment with an HIV-RNA &lt;\u200950 cp\/mL at the time of the switch to TAF\/FTC\/RPV, TAF\/FTC\/EVG\/cobi and ABC\/3TC\/DTG were retrospectively included in the analysis. Framingham risk score modification after 12\u2009months from the switch such as lipid profile and body weight modification were assessed. The change from baseline to 12\u2009months in mean cardiovascular risk and body weight in each of the STR\u2019s group were assessed by means of Wilcoxon signed-rank test whereas a mixed regression model was used to assess variation in lipid levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five-hundred and sixty PLWH were switched to an STR regimen of whom 170 (30.4%) to TAF\/FTC\/EVG\/cobi, 191 (34.1%) to TAF\/FTC\/RPV and 199 (35.5%) to ABC\/3TC\/DTG.<\/jats:p>\n                <jats:p>No difference in the Framingham cardiovascular risk score was observed after 12\u2009months from the switch in each of the STR\u2019s groups. No significant overtime variation in mean total cholesterol levels from baseline to 12\u2009months was observed for PLWH switched to ABC\/3TC\/DTG [200 (SD 38) mg\/dl vs 201 (SD 35) mg\/dl; <jats:italic>p<\/jats:italic>\u2009=\u20090.610] whereas a significant increment was observed in PLWH switched to TAF\/FTC\/EVG\/cobi [192 (SD 34) mg\/dl vs 208 (SD 40) mg\/dl; <jats:italic>p\u2009&lt;\u20090.0001<\/jats:italic>] and TAF\/FTC\/RPV [187 (SD 34) mg\/dl vs 195 (SD 35) mg\/dl; <jats:italic>p\u2009=\u20090.027<\/jats:italic>]. In addition, a significant variation in the mean body weight from baseline to 12\u2009months was observed in PLWH switched to TAF\/FTC\/EVG\/cobi [72.2 (SD 13.5) kilograms vs 74.6 (SD 14.3) kilograms; <jats:italic>p\u2009&lt;\u20090.0001<\/jats:italic>] and TAF\/FTC\/RPV [73.4 (SD 11.6) kilograms vs 75.6 (SD 11.8) kilograms; <jats:italic>p\u2009&lt;\u20090.0001<\/jats:italic>] whereas no difference was observed in those switched to ABC\/3TC\/DTG [71.5 (SD 12.8) kilograms vs 72.1 (SD 12.6) kilograms; <jats:italic>p<\/jats:italic>\u2009=\u20090.478].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>No difference in the cardiovascular risk after 1\u00a0year from the switch to these STRs were observed. PLWH switched to TAF\/FTC\/EVG\/cobi and TAF\/FTC\/RPV showed an increase in total cholesterol levels and body weight 12\u2009months after the switch.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06304-3","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:02:48Z","timestamp":1624366968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of switching to TAF\/FTC\/RPV, TAF\/FTC\/EVG\/cobi and ABC\/3TC\/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Andrea","family":"Giacomelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pezzati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Oreni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lisa","family":"Ridolfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Morena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Bonazzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"6","key":"6304_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/QAD.0b013e32835cae9c","volume":"27","author":"AJ Rodger","year":"2013","unstructured":"Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973\u20139. https:\/\/doi.org\/10.1097\/QAD.0b013e32835cae9c.","journal-title":"AIDS"},{"issue":"8","key":"6304_CR2","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1086\/521935","volume":"45","author":"RC Kaplan","year":"2007","unstructured":"Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45(8):1074\u201381. https:\/\/doi.org\/10.1086\/521935.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"6304_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa062744","volume":"356","author":"N Friis-Moller","year":"2007","unstructured":"Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723\u201335. https:\/\/doi.org\/10.1056\/NEJMoa062744.","journal-title":"N Engl J Med"},{"issue":"9","key":"6304_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/00002030-200306130-00007","volume":"17","author":"D Nolan","year":"2003","unstructured":"Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, et al. DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17(9):1329\u201338. https:\/\/doi.org\/10.1097\/00002030-200306130-00007.","journal-title":"AIDS"},{"issue":"7","key":"6304_CR5","doi-asserted-by":"publisher","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51\u20138. https:\/\/doi.org\/10.1097\/00002030-199807000-00003.","journal-title":"AIDS."},{"issue":"3","key":"6304_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/00126334-200407010-00007","volume":"36","author":"VE Stone","year":"2004","unstructured":"Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808\u201316. https:\/\/doi.org\/10.1097\/00126334-200407010-00007.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"6304_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.24875\/AIDSRev.M18000025","volume":"20","author":"P Domingo","year":"2018","unstructured":"Domingo P, Mateo MG, Gutierrez MDM, Vidal F. Tolerability of current antiretroviral single-tablet regimens. AIDS Rev. 2018;20(3):141\u20139. https:\/\/doi.org\/10.24875\/AIDSRev.M18000025.","journal-title":"AIDS Rev"},{"issue":"3","key":"6304_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40271-015-0123-2","volume":"8","author":"J Brunetta","year":"2015","unstructured":"Brunetta J, Moreno Guill\u00e9n S, Antinori A, Yeni P, Wade B, Johnson M, et al. Patient-reported outcomes after a switch to a single-tablet regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-positive, Virologically suppressed individuals: additional findings from a randomized, open-label, 48-week trial. Patient. 2015;8(3):257\u201367. https:\/\/doi.org\/10.1007\/s40271-015-0123-2.","journal-title":"Patient."},{"issue":"5","key":"6304_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"AM Hall","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773\u201380. https:\/\/doi.org\/10.1053\/j.ajkd.2011.01.022.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6304_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/QAI.0000000000001558","volume":"77","author":"D Cattaneo","year":"2018","unstructured":"Cattaneo D, Minisci D, Baldelli S, Mazzali C, Giacomelli A, Milazzo L, et al. Effect of Cobicistat on Tenofovir Disoproxil fumarate (TDF): what is true for TAF may also be true for TDF. J Acquir Immune Defic Syndr. 2018;77(1):86\u201392. https:\/\/doi.org\/10.1097\/QAI.0000000000001558.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"6304_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/hiv.12688","volume":"20","author":"G Baldin","year":"2019","unstructured":"Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, et al. Efficacy and safety of switching to dolutegravir plus emtricitabine\/tenofovir disoproxil fumarate (TDF) or elvitegravir\/cobicistat\/emtricitabine\/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. HIV Med. 2019;20(2):164\u20138. https:\/\/doi.org\/10.1111\/hiv.12688.","journal-title":"HIV Med"},{"issue":"10","key":"6304_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/hiv.12664","volume":"19","author":"D Hagins","year":"2018","unstructured":"Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19(10):724\u201333. https:\/\/doi.org\/10.1111\/hiv.12664.","journal-title":"HIV Med"},{"issue":"1","key":"6304_CR13","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"C Orkin","year":"2018","unstructured":"Orkin C, Molina JM, Negredo E. Et al; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23\u201334. https:\/\/doi.org\/10.1016\/S2352-3018(17)30179-0.","journal-title":"Lancet HIV"},{"issue":"4","key":"6304_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/aid.2017.0203","volume":"34","author":"E DeJesus","year":"2018","unstructured":"DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, et al. Superior efficacy and improved renal and bone safety after switching from a Tenofovir Disoproxil fumarate- to a Tenofovir Alafenamide-based regimen through 96 weeks of treatment. AIDS Res Hum Retrovir. 2018;34(4):337\u201342. https:\/\/doi.org\/10.1089\/aid.2017.0203.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"4","key":"6304_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/cid\/ciy505","volume":"68","author":"JM Gatell","year":"2019","unstructured":"Gatell JM, Assoumou L, Moyle G, et al. European Network for AIDS Treatment 022 (NEAT022) Study Group. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age \u226550 Years: Final 96-Week Results of the NEAT022 Study. Clin Infect Dis. 2019;68(4):597\u2013606. https:\/\/doi.org\/10.1093\/cid\/ciy505.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6304_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3851\/IMP3192","volume":"22","author":"B Trottier","year":"2017","unstructured":"Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, et al. Correction: Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22(5):459\u201360. https:\/\/doi.org\/10.3851\/IMP3192.","journal-title":"Antivir Ther"},{"issue":"4","key":"6304_CR17","first-page":"443","volume":"38","author":"M Andreoni","year":"2015","unstructured":"Andreoni M, Marcotullio S, Puro V, de Carli G, Tambussi G, Nozza S, et al. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project New Microbiol. 2015;38(4):443\u201390.","journal-title":"The NEXTaim Project New Microbiol"},{"key":"6304_CR18","doi-asserted-by":"crossref","unstructured":"Tungsiripat M, Kitch D, Glesby MJ , et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781\u20134.","DOI":"10.1097\/QAD.0b013e32833ad8b4"},{"issue":"3","key":"6304_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/jac\/dkq464","volume":"66","author":"M Fabbiani","year":"2011","unstructured":"Fabbiani M, Bracciale L, Doino M, Sidella L, Farina S, Di Cristo V, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother. 2011;66(3):682\u20133. https:\/\/doi.org\/10.1093\/jac\/dkq464.","journal-title":"J Antimicrob Chemother"},{"key":"6304_CR20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2147\/DDDT.S204415","volume":"13","author":"A Giacomelli","year":"2019","unstructured":"Giacomelli A, Ranzani A, Oreni L, et al. Durability of INI-containing regimens after switching from PI-containing regimens: a single-Centre cohort of drug-experienced HIV-infected subjects. Drug Des Devel Ther. 2019;13:2271\u201382.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"6304_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.699579.","journal-title":"Circulation."},{"issue":"1","key":"6304_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12879-017-2510-x","volume":"17","author":"GV De Socio","year":"2017","unstructured":"De Socio GV, Pucci G, Baldelli F, Schillaci G. Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study. BMC Infect Dis. 2017;17(1):414. https:\/\/doi.org\/10.1186\/s12879-017-2510-x.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"6304_CR23","first-page":"401","volume":"74","author":"JM Lewis","year":"2017","unstructured":"Lewis JM, Smith C, Torkington A, et al. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study. J Inf Secur. 2017;74(4):401\u20137.","journal-title":"J Inf Secur"},{"key":"6304_CR24","doi-asserted-by":"publisher","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and Management of Cardiovascular Disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98\u2013124. https:\/\/doi.org\/10.1161\/CIR.0000000000000695.","DOI":"10.1161\/CIR.0000000000000695"},{"key":"6304_CR25","doi-asserted-by":"publisher","first-page":"969281","DOI":"10.1155\/2013\/969281","volume":"2013","author":"MW Nery","year":"2013","unstructured":"Nery MW, Martelli CM, Silveira EA, et al. Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. ScientificWorldJournal. 2013;2013:969281.","journal-title":"ScientificWorldJournal."},{"issue":"11","key":"6304_CR26","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1093\/jac\/dkaa292","volume":"75","author":"A Gonzalez-Cordon","year":"2020","unstructured":"Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, et al. Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. J Antimicrob Chemother. 2020;75(11):3334\u201343. https:\/\/doi.org\/10.1093\/jac\/dkaa292.","journal-title":"J Antimicrob Chemother"},{"key":"6304_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","volume":"92","author":"PH Kuo","year":"2020","unstructured":"Kuo PH, Sun HY, Chuang YC, Wu PY, Liu WC, Hung CC. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide. Int J Infect Dis. 2020;92:71\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2019.12.029.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"6304_CR28","doi-asserted-by":"publisher","first-page":"ofaa195","DOI":"10.1093\/ofid\/ofaa195","volume":"7","author":"L Taramasso","year":"2020","unstructured":"Taramasso L, Bonfanti P, Ricci E, et al. Factors Associated With Weight Gain in People Treated With Dolutegravir. Open Forum Infect Dis. 2020;7(6):ofaa195.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"6304_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","volume":"76","author":"J Norwood","year":"2017","unstructured":"Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from Efavirenz-based to integrase Strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527\u201331. https:\/\/doi.org\/10.1097\/QAI.0000000000001525.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"6304_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/cid\/cir510","volume":"53","author":"JK Rockstroh","year":"2011","unstructured":"Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807\u201316. https:\/\/doi.org\/10.1093\/cid\/cir510.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6304_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2055-6640(20)30277-6","volume":"5","author":"A Hill","year":"2019","unstructured":"Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019;5(1):41\u20133. https:\/\/doi.org\/10.1016\/S2055-6640(20)30277-6.","journal-title":"J Virus Erad"},{"key":"6304_CR32","doi-asserted-by":"publisher","unstructured":"Lahiri C, Xu Y, Wang K, et al. Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV [published online ahead of print, 2020 Nov 24]. AIDS Res Hum Retrovir. 2020. https:\/\/doi.org\/10.1089\/AID.2020.0197.","DOI":"10.1089\/AID.2020.0197"},{"key":"6304_CR33","volume-title":"23rd International AIDS Conference, abstract 3283","author":"P Mallon","year":"2020","unstructured":"Mallon P, et al. Weight gain before and after switch from TDF to TAF. In: 23rd International AIDS Conference, abstract 3283; 2020."},{"key":"6304_CR34","doi-asserted-by":"publisher","unstructured":"Surial B, Mugglin C, Calmy A, et al. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study [published online ahead of print, 2021 Mar 16]. Ann Intern Med. 2021. https:\/\/doi.org\/10.7326\/M20-4853.","DOI":"10.7326\/M20-4853"},{"key":"6304_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ahj.2018.11.012","volume":"209","author":"RA Riestenberg","year":"2019","unstructured":"Riestenberg RA, Furman A, Cowen A, Pawlowksi A, Schneider D, Lewis AA, et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J. 2019;209:79\u201387. https:\/\/doi.org\/10.1016\/j.ahj.2018.11.012.","journal-title":"Am Heart J"},{"issue":"8","key":"6304_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11908-018-0628-7","volume":"20","author":"M Mosepele","year":"2018","unstructured":"Mosepele M, Molefe-Baikai OJ, Grinspoon SK, Triant VA. Benefits and Risks of Statin Therapy in the HIV-Infected Population. Curr Infect Dis Rep. 2018;20(8):20 Published 2018 May 26.","journal-title":"Curr Infect Dis Rep"},{"key":"6304_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jcte.2017.01.004","volume":"8","author":"DB Chastain","year":"2017","unstructured":"Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;8:6\u201314. https:\/\/doi.org\/10.1016\/j.jcte.2017.01.004.","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"6304_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-018-3162-1","volume":"18","author":"OA Uthman","year":"2018","unstructured":"Uthman OA, Nduka C, Watson SI, Mills EJ, Kengne AP, Jaffar SS, et al. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):258. https:\/\/doi.org\/10.1186\/s12879-018-3162-1.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6304_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12981-019-0226-2","volume":"16","author":"P Maggi","year":"2019","unstructured":"Maggi P, De Socio GV, Cicalini S, et al. Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. AIDS Res Ther. 2019;16(1):11. https:\/\/doi.org\/10.1186\/s12981-019-0226-2.","journal-title":"AIDS Res Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06304-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T13:03:08Z","timestamp":1624366988000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06304-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6304"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06304-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Comitato Etico Interaziendale Milano Area 1 (Local IRB). All methods were performed in accordance with the relevant guidelines and regulations. A dedicated informed consent was obtained by all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AG received consultancy fees from Mylan and non-financial educational support and research Grant from Gilead. SR received grants, fees for speaker\u2019s bureau, advisory boards and CME activities from BMS, ViiV, MSD, Mylan, Gilead, Janssen. MG received grants, fees for speaker\u2019s bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. LO, LP, FC, VM, CB, GP and ALR has nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"595"}}